Medicines/Item |
Section |
Status |
Link Name / Link URL |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA 300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis |
Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
Adalimumab injection |
11.04.02 |
Formulary
|
NICE TA 460 Adalimumab and dexamethasone for treating non-infectious uveitis |
Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
Adrenaline (epinephrine) injection |
03.04.03 |
Formulary
|
NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment |
Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA 346 Aflibercept for treating diabetic macular oedema |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA 305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA 294 Aflibercept solution for injection for treating wet age‑related macular degeneration |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA 486 Aflibercept for treating choroidal neovascularisation |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
Alemtuzumab |
08.02.03 |
Non Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Alitretinoin |
13.05.01 |
Formulary
|
NICE TA 177 Alitretinoin for the treatment of severe chronic hand eczema |
Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
Anastrozole |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Anti-D in pregnant women |
Apixaban |
02.08.02 |
Formulary
|
NICE TA341 - DVT and PE treatment and secondary prevention |
Apixaban |
02.08.02 |
Formulary
|
NICE TA245 - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
Apixaban |
02.08.02 |
Formulary
|
NICE TA275 - Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
Apremilast |
13.05.03 |
Formulary
|
NICE TA 433 Apremilast for treating active psoriatic arthritis |
Apremilast |
13.05.03 |
Formulary
|
NICE TA419 Apremilast for treating moderate to severe plaque psoriasis |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526 Arsenic trioxide for treating acute promyelocytic leukaemia |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA525 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA 520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA 639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA 666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma |
Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
Avelumab |
08.01.05 |
Formulary
|
NICE TA 517 Avelumab for treating metastatic Merkel cell carcinoma |
Avelumab |
08.01.05 |
Formulary
|
NICE TA 645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
Axicabtagene ciloleucel |
08.01.05 |
Formulary
|
NICE TA 559 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
Axitinib |
08.01.05 |
Formulary
|
NICE TA 645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
Baricitinib tablets |
10.01.03 |
Formulary
|
TA 466 Baricitinib for moderate to severe rheumatoid arthritis |
Basiliximab |
08.02.02 |
Formulary
|
NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people |
Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
Belimumab |
10.01.03 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
Bendamustine |
08.01.01 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA 666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma |
Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA263: Breast cancer with capecitabine |
Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA214: Breast Cancer with taxane |
Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
Binimetinib |
08.01.05 |
Formulary
|
NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
Blinatumomab |
08.02.03 |
Formulary
|
NICE TA 589 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
Blinatumomab |
08.02.03 |
Formulary
|
NICE TA 450 Blinatumomab for previously treated Philadelphia-chromosome-negative ALL |
Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: 1st line treatment of multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA 260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA 478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA 641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
Brigatinib |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
Brigatinib |
08.01.05 |
Formulary
|
NICE TA 670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor |
Brodalumab |
13.05.03 |
Formulary
|
NICE TA 511 Brodalumab for treating moderate to severe plaque psoriasis |
Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542 Cabozantinib for untreated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA 463 Cabozantinib for previously treated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA 516 Cabozantinib for treating medullary thyroid cancer |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Cangrelor |
02.09 |
Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
Cannabidiol |
04.08.01 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
Cannabidiol |
04.08.01 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
Cannabis extract |
10.02.02 |
Formulary
|
NICE NG144 Cannabis-based medicinal products |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
Caplacizumab |
09.01 |
Formulary
|
NICE TA 667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
Capsaicin 0.025% cream |
10.03.02 |
Formulary
|
NICE CG 177: Osteoarthritis: care and management |
Capsaicin 0.075% cream |
10.03.02 |
Formulary
|
NICE CG 173: Neuropathic pain in adults: pharmacological management in non-specialist settings |
Carboplatin |
08.01.05 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
Carfilzomib |
08.01.05 |
Formulary
|
NICE TA 657 Carfilzomib for previously treated multiple myeloma |
Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Cemiplimab |
08.01.05 |
Formulary
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445 Certolizumab pegol and secukinumab for psoriatic arthritis after inadequate response to DMARDs |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA 668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA 473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
Ciclosporin eye drops |
11.99.99.99 |
Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
Clopidogrel |
02.09 |
Formulary
|
NICE TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA 414 Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
Colistimethate sodium inhaler |
05.01.07 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Collagenase clostridium histolyticum |
10.03.01 |
Non Formulary
|
NICE TA 459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA 422 Crizotinib for previously treated ALK-positive advanced non-small-cell lung cancer |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA157 - Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Daclatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
Daclizumab |
08.02.02 |
Non Formulary
|
NICE TA 441 Daclizumab for treating relapsing–remitting multiple sclerosis |
Dacomitinib monohydrate |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 418 Dapagliflozin in triple therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
Daratumumab |
08.01.05 |
Formulary
|
NICE TA 510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
Daratumumab |
08.01.05 |
Formulary
|
NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
Darolutamide |
08.03.04.02 |
Formulary
|
NICE TA 660 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
Dasabuvir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Dasatinib |
08.01.05 |
Formulary
|
NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Dasatinib |
08.01.05 |
Formulary
|
NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab |
Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA349: Diabetic Macular Oedema |
Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 460 Adalimumab and dexamethasone for treating non-infectious uveitis |
Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 229 Dexamethasone intravitreal implant for macular oedema secondary to retinal vein occlusion |
Diclofenac Gel 1% |
10.03.02 |
Formulary
|
NICE CG 177: Osteoarthritis: care and management |
Dimethyl fumarate |
08.02.04 |
Non Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
Dimethyl fumarate |
13.05.03 |
Formulary
|
NICE TA 475 Dimethyl fumarate for treating moderate to severe plaque psoriasis |
Dipyridamole MR capsules |
02.09 |
Formulary
|
NICE TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
Docetaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
Durvalumab |
08.01.05 |
Formulary
|
NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
Eculizumab |
09.01.03 |
Formulary
|
NICE HST 1 Eculizumab for treating atypical haemolytic uraemic syndrome |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA355 - Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA354 - Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
Elbasvir/grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413 Elbasvir–grazoprevir for treating chronic hepatitis C |
Eltrectinib |
08.01.05 |
Formulary
|
NICE TA 644: Entrectinib for treating NTRK fusion-positive solid tumours |
Eltrectinib |
08.01.05 |
Formulary
|
NICE TA 643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
Eluxadoline |
01.05 |
Formulary
|
NICE TA 471 Eluxadoline for treating irritable bowel syndrome with diarrhoea |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
Encorafenib |
08.01.05 |
Formulary
|
NICE TA 668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer |
Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Eplerenone tablets |
02.02.03 |
Formulary
|
NICE NG106: Chronic heart failure in adults: diagnosis and management |
Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Epoetin alfa |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Epoetin beta |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
Eribulin |
08.01.05 |
Formulary
|
NICE TA 423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
Eribulin |
08.01.05 |
Non Formulary
|
NICE TA 515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA 258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA 374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
10.01.03 |
Formulary
|
NICE TA35: Adult psoriasis |
Etanercept (biosimilar) injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept (biosimilar) injection |
13.05.03 |
Formulary
|
NICE TA 103 Etanercept and efalizumab for the treatment of adults with psoriasis |
Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA35: Adult psoriasis |
Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept injection |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
Etelcalcetide |
09.05.01.02 |
Formulary
|
NICE TA 448 Etelcalcetide for treating secondary hyperparathyroidism |
Etoposide |
08.01.04 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
Everolimus |
08.01.05 |
Formulary
|
NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours |
Everolimus |
08.01.05 |
Formulary
|
NICE TA 432 Everolimus for advanced renal cell carcinoma after previous treatment |
Everolimus |
08.01.05 |
Formulary
|
NICE TA 421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Exemestane |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
Exemestane |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
Exenatide prolonged release |
06.01.02.03 |
Formulary
|
NICE NG 28: Type 2 diabetes in adults: management |
Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
Finasteride |
06.04.02 |
Formulary
|
NICE CG97 Lower urinary tract symptoms: quick reference guide |
Fingolimod |
08.02.04 |
Non Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 590 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 301 diabetic macular oedema |
Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA 659 Galcanezumab for preventing migraine |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Gemcitabine |
08.01.03 |
Formulary
|
Pancreatic cancer in adults: diagnosis and management |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Gemtuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
Gilteritinib |
08.01.05 |
Formulary
|
NICE TA 642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
Glecaprevir/Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
Golimumab |
10.01.03 |
Formulary
|
NICE TA220: psoriatic arthritis |
Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Guselkumab |
13.05.03 |
Formulary
|
NICE TA 521: Guselkumab for treating moderate to severe plaque psoriasis |
Holoclar® |
11.99.99.99 |
Formulary
|
NICE TA 467 Holoclar for treating limbal stem cell deficiency after eye burns |
Ibandronic Acid |
06.06.02 |
Restricted Use
|
NICE TA464 - Bisphosphonates for treating osteoporosis |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA 429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA 491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
Ibuprofen gel |
10.03.02 |
Formulary
|
NICE CG 177: Osteoarthritis: care and management |
Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
Imatinib |
08.01.05 |
Formulary
|
NICE TA 209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
Imatinib |
08.01.05 |
Formulary
|
NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Imatinib |
08.01.05 |
Formulary
|
NICE TA 86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
Imatinib |
08.01.05 |
Formulary
|
NICE TA 70 Guidance on the use of imatinib for chronic myeloid leukaemia |
Imatinib |
08.01.05 |
Formulary
|
NICE TA 326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA 187 Infliximab and adalimumab for the treatment of Crohn’s disease |
Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA 329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis |
Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab (biosimilar) for infusion |
13.05.03 |
Formulary
|
NICE TA 134 Infliximab for the treatment of adults with psoriasis |
Infliximab (biosimilar) for infusion |
13.05.03 |
Formulary
|
NICE TA 134 Infliximab for the treatment of adults with psoriasis |
Infliximab for infusion |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
Interferon beta-1a |
10.02 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
Interferon beta-1b |
10.02.01 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
Irinotecan (pegylated liposomal) |
08.01 |
Non Formulary
|
NICE TA 440 Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
Irinotecan Hydrochloride |
08.01.05 |
Formulary
|
NICE CG 131 Colorectal cancer: diagnosis and management |
Isatuximab |
08.01.05 |
Formulary
|
NICE TA 658 Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
Ivabradine |
02.06.03 |
Formulary
|
NICE TA 267 Ivabradine for treating chronic heart failure |
Ixazomib |
08.02.04 |
Formulary
|
TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
Ixekizumab injection |
13.05.03 |
Formulary
|
NICE TA 442 Ixekizumab for treating moderate to severe plaque psoriasis |
Ixekizumab injection |
13.05.03 |
Formulary
|
NICE TA 537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Lamivudine |
05.03.01 |
Formulary
|
NICE CG165: Chronic Hepatitis B |
Lanadelumab |
03.04.03 |
Formulary
|
TA 606 Lanadelumab for preventing recurrent attacks of hereditary angioedema |
Lapatinib |
08.01.05 |
Restricted Use
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Larotrectinib |
08.01.05 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 171 Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA 551 Lenvatinib for untreated advanced hepatocellular carcinoma |
Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA 535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
Letermovir |
05.03.02.02 |
Formulary
|
NICE TA 591 Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
Letrozole |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
Letrozole |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and treatment |
Lidocaine medicated plaster 5% |
15.02 |
Restricted Use
|
NICE CG173 - Neuropathic pain in adults: pharmacological management in non-specialist settings |
Liposomal cytarabine-daunorubicin |
08.01.05 |
Formulary
|
NICE TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA 664 Liraglutide for managing overweight and obesity |
Lorlatinib |
08.01.05 |
Formulary
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA 431 Mepolizumab for treating severe refractory eosinophilic asthma |
Methadone Hydrochloride |
04.10 |
Formulary
|
NICE TA 114 Methadone and Buprenorphine for management of opioid dependence |
Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
Midostaurin |
08.01.05 |
Formulary
|
Midostaurin for untreated acute myeloid leukaemia |
Mifamurtide |
08.02.04 |
Non Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
Naldemedine |
01.06.06 |
Formulary
|
NICE TA 651: Naldemedine for treating opioid-induced constipation |
Nalmefene |
04.10.01 |
Formulary
|
NICE TA 325 Reduction of alcohol consumption in alcohol dependence |
Naloxegol |
01.06.06 |
Formulary
|
NICE TA 345 Naloxegol for treating opioid‑induced constipation |
Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
Naltrexone Hydrochloride |
04.10 |
Formulary
|
NICE TA 115 Naltrexone for management of opioid dependence |
Natalizumab |
08.02.04 |
Non Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
Neratinib |
08.01.05 |
Formulary
|
NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Nintedanib |
03.11 |
Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
Nintedanib |
03.11 |
Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
Nintedanib |
08.01.05 |
Formulary
|
NICE TA 347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
Niraparib |
08.01.05 |
Formulary
|
NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA417 Nivolumab for previously treated advanced renal cell carcinoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA558 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA 655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
Nusinersen |
10.02 |
Formulary
|
NICE TA 588 Nusinersen for treating spinal muscular atrophy |
Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA 443 Obeticholic acid for treating primary biliary cholangitis |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA 513 Obinutuzumab for untreated advanced follicular lymphoma |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA 663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
Ocrelizumab |
08.02.04 |
Formulary
|
NICE TA 533 Ocrelizumab for treating relapsing–remitting multiple sclerosis |
Ocrelizumab |
08.02.04 |
Formulary
|
NICE TA 585: Ocrelizumab for treating primary progressive multiple sclerosis |
Ocriplasmin |
11.08.02 |
Formulary
|
NICE TA 297 Ocriplasmin for treating vitreomacular traction |
Ofatumumab |
08.02.03 |
Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
Olaparib |
08.02.04 |
Formulary
|
NICE TA620 Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
Olaparib |
08.02.04 |
Formulary
|
NICE TA598 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
Olaratumab |
08.01.05 |
Non Formulary
|
NICE TA 465 Olaratumab with doxorubicin for treating advanced soft tissue sarcoma |
Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Oseltamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
Oseltamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
Osimertinib |
08.02.04 |
Formulary
|
NICE TA 416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
Osimertinib |
08.02.04 |
Formulary
|
NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
Osimertinib |
08.02.04 |
Formulary
|
NICE TA 654:Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Pabrinex® |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
Pabrinex® |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
Paclitaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA 476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA 639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Panitumumab |
08.01.05 |
Formulary
|
NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
Patiromer |
09.02.01.01 |
Formulary
|
NICE TA623 Patiromer for treating hyperkalaemia |
Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
Pegaspargase |
08.01 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
Peginterferon beta 1a |
10.02.01 |
Formulary
|
NICE TA624 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA522Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 661 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
Pentosan polysulfate sodium capsules |
07.04.03 |
Formulary
|
NICE TA610 Pentosan polysulfate sodium for treating bladder pain syndrome |
Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA 424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
Pimecrolimus 1% cream |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Piracetam |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
Pirfenidone |
03.11 |
Formulary
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy |
Polatuzumab vedotin |
08.01.05 |
Formulary
|
NICE TA 649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
Pomalidomide |
08.02.04 |
Formulary
|
NICE TA 427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
Pomalidomide |
08.02.04 |
Formulary
|
NICE TA 658 Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
Ponatinib |
08.01.05 |
Formulary
|
NICE TA 451 Ponatinib for treating CML and ALL |
Prasugrel |
02.09 |
Formulary
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA 160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA 161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 274 Ranibizumab for treating diabetic macular oedema |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
Regorafenib |
08.01.05 |
Formulary
|
NICE TA 488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
Regorafenib |
08.01.05 |
Formulary
|
NICE TA 555 Regorafenib for previously treated advanced hepatocellular carcinoma |
Regorafenib |
08.01.05 |
Non Formulary
|
NICE TA 514 Regorafenib for previously treated advanced hepatocellular carcinoma |
Reslizumab |
03.04.02 |
Formulary
|
NICE TA 479 Reslizumab for treating severe eosinophilic asthma |
Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
Ribociclib |
08.03.04.01 |
Restricted Use
|
NICE TA 593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Rifaximin |
05.01.07 |
Formulary
|
NICE TA 337 Rifaximin for preventing episodes of overt hepatic encephalopathy |
Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma |
Rituximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Rituximab |
10.01.03 |
Formulary
|
NICE TA 308 - ANCA vasculitis |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170 - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256 - Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261 - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287 - Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
Roflumilast |
03.03.03 |
Formulary
|
TA 461 Roflumilast for treating chronic obstructive pulmonary disease |
Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
Rucaparib |
08.01.05 |
Formulary
|
NICE TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
Secukinumab injection |
10.01.03 |
Formulary
|
NICE TA 445 Certolizumab pegol and secukinumab for psoriatic arthritis after inadequate response to DMARDs |
Secukinumab injection |
10.01.03 |
Formulary
|
NICE TA 407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
Secukinumab injection |
13.05.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
Secukinumab injection |
13.05.03 |
Formulary
|
NICE TA350: Plaque Psoriasis |
Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
Siponimod |
08.02.04 |
Formulary
|
NICE TA 656: Siponimod for treating secondary progressive multiple sclerosis |
Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
Sofosbuvir/velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA 430 Sofosbuvir–velpatasvir for treating chronic hepatitis C |
sofosbuvir/velpatasvir/voxilaprevir |
05.03.03.02 |
Formulary
|
TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Somatropin for growth failure in children |
Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
Sorafenib |
08.01.05 |
Formulary
|
NICE TA 474 Sorafenib for treating advanced hepatocellular carcinoma |
Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
Stiripentol |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) |
Talimogene laherparepvac |
08.02.04 |
Formulary
|
NICE TA 410 Talimogene laherparepvec for treating unresectable metastatic melanoma |
Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
Tamoxifen |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
Tamoxifen |
08.03.04.01 |
Formulary
|
NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
Tamoxifen |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and treatment |
Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
Teriflunomide |
08.02.04 |
Non Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
Ticagrelor |
02.09 |
Formulary
|
NICE TA 420 Ticagrelor for preventing atherothrombotic events after myocardial infarction |
Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis |
Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
Tivozanib |
08.01.05 |
Formulary
|
NICE TA 512 Tivozanib for treating advanced renal cell carcinoma |
Tobramycin inhaler |
05.01.04 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247:Tocilizumab in RA |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA 518 Tocilizumab for treating giant cell arteritis |
Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480: tofacitinib for moderate to severe rheumatoid arthritis |
Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
Topotecan |
08.01.05 |
Formulary
|
TA 183 Topotecan for the treatment of recurrent and stage IVB cervical cancer |
Topotecan |
08.01.05 |
Formulary
|
NICE TA 389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
Trabectedin |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA 458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer |
Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
Treosulfan |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
Trifluridine-tiparicil tablets |
08.01.03 |
Formulary
|
NICE TA 405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
Trifluridine-tiparicil tablets |
08.01.03 |
Formulary
|
NICE TA 669: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies |
Upadacitinib |
10.01.03 |
Formulary
|
NICE TA 665: Upadacitinib for treating severe rheumatoid arthritis |
UrgoStart® |
19.20 |
Formulary
|
NICE MTG 40: UrgoStart for treating diabetic foot ulcers and leg ulcers |
Ustekinumab |
01.05.03 |
Formulary
|
NICE TA 456 Ustekinumab for moderately to severely active Crohn’s disease |
Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
Ustekinumab |
10.01.03 |
Formulary
|
NICE TA 340 Ustekinumab for treating active psoriatic arthritis |
Ustekinumab injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Ustekinumab injection |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
Ustekinumab injection |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA 487 Venetoclax for treating chronic lymphocytic leukaemia |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA 663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
Verteporfin |
11.08.02 |
Formulary
|
NICE NG82: Age-related macular degeneration |
Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
Zanamivir inhalation |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
Zanamivir inhalation |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |